AE Wealth Management LLC Has $347,000 Stake in Solventum Corporation $SOLV

AE Wealth Management LLC lowered its position in shares of Solventum Corporation (NYSE:SOLV) by 14.7% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,571 shares of the company’s stock after selling 787 shares during the period. AE Wealth Management LLC’s holdings in Solventum were worth $347,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Independent Franchise Partners LLP increased its position in Solventum by 263.1% during the 1st quarter. Independent Franchise Partners LLP now owns 5,820,724 shares of the company’s stock worth $442,608,000 after buying an additional 4,217,570 shares during the period. Boston Partners grew its stake in shares of Solventum by 101.3% in the first quarter. Boston Partners now owns 3,361,973 shares of the company’s stock valued at $255,554,000 after acquiring an additional 1,691,565 shares in the last quarter. Nuveen LLC acquired a new position in shares of Solventum in the first quarter valued at about $35,375,000. Diamond Hill Capital Management Inc. increased its position in Solventum by 139.6% during the first quarter. Diamond Hill Capital Management Inc. now owns 577,173 shares of the company’s stock worth $43,888,000 after acquiring an additional 336,282 shares during the period. Finally, Lord Abbett & CO. LLC acquired a new stake in Solventum in the 1st quarter worth about $23,572,000.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on SOLV. Zacks Research upgraded shares of Solventum from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 15th. Wells Fargo & Company boosted their price target on Solventum from $79.00 to $82.00 and gave the company an “equal weight” rating in a research note on Monday, September 15th. Weiss Ratings reissued a “hold (c)” rating on shares of Solventum in a research report on Thursday, October 30th. Wall Street Zen lowered Solventum from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Piper Sandler lifted their price objective on Solventum from $94.00 to $98.00 and gave the company an “overweight” rating in a report on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $85.56.

Solventum Stock Performance

NYSE:SOLV opened at $75.59 on Friday. Solventum Corporation has a twelve month low of $60.70 and a twelve month high of $85.92. The company has a quick ratio of 1.14, a current ratio of 1.50 and a debt-to-equity ratio of 1.03. The stock’s 50-day simple moving average is $72.14 and its 200 day simple moving average is $72.70. The firm has a market capitalization of $13.11 billion, a PE ratio of 8.71, a price-to-earnings-growth ratio of 2.93 and a beta of 0.48.

Solventum (NYSE:SOLV) last posted its earnings results on Thursday, November 6th. The company reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.43 by $0.07. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The firm had revenue of $2.10 billion during the quarter, compared to analysts’ expectations of $2.05 billion. During the same quarter in the prior year, the business earned $1.64 earnings per share. The business’s revenue for the quarter was up .7% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. On average, analysts anticipate that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.